- Home
- AVTX vs EDSA Comparison
AVTX vs EDSA Comparison
Compare AVTX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- EDSA
- Stock Information
- Founded
- AVTX 2011
- EDSA 2015
- Country
- AVTX United States
- EDSA Canada
- Employees
- AVTX N/A
- EDSA N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- EDSA Health Care
- Exchange
- AVTX Nasdaq
- EDSA Nasdaq
- Market Cap
- AVTX 90.9M
- EDSA 13.7M
- IPO Year
- AVTX 2015
- EDSA N/A
- Fundamental
- Price
- AVTX $9.47
- EDSA $4.32
- Analyst Decision
- AVTX Buy
- EDSA Strong Buy
- Analyst Count
- AVTX 1
- EDSA 2
- Target Price
- AVTX $35.00
- EDSA $39.00
- AVG Volume (30 Days)
- AVTX 13.2K
- EDSA 8.4K
- Earning Date
- AVTX 11-07-2024
- EDSA 08-09-2024
- Dividend Yield
- AVTX N/A
- EDSA N/A
- EPS Growth
- AVTX N/A
- EDSA N/A
- EPS
- AVTX N/A
- EDSA N/A
- Revenue
- AVTX $807,000.00
- EDSA N/A
- Revenue This Year
- AVTX N/A
- EDSA N/A
- Revenue Next Year
- AVTX N/A
- EDSA N/A
- P/E Ratio
- AVTX N/A
- EDSA N/A
- Revenue Growth
- AVTX N/A
- EDSA N/A
- 52 Week Low
- AVTX $3.95
- EDSA $2.46
- 52 Week High
- AVTX $45.12
- EDSA $8.33
- Technical
- Relative Strength Index (RSI)
- AVTX 51.19
- EDSA 53.46
- Support Level
- AVTX $8.49
- EDSA $4.22
- Resistance Level
- AVTX $10.20
- EDSA $5.00
- Average True Range (ATR)
- AVTX 0.66
- EDSA 0.25
- MACD
- AVTX 0.11
- EDSA 0.04
- Stochastic Oscillator
- AVTX 60.75
- EDSA 53.06
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.